• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Roger Perl­mut­ter’s lat­est ‘re­tire­ment’ gig opens a door to the bustling Chi­na biotech scene

5 years ago
Bioregnum
China

CAR-M era be­gins as Caris­ma dos­es first pa­tient

5 years ago
Cell/Gene Tx

Covid-19 roundup: Fac­ing sup­ply de­lay, UK fires shot at Eu­rope af­ter EU threat­ens to ban As­traZeneca vac­cine ex­ports

5 years ago
Coronavirus

Are ra­dio­phar­ma­ceu­ti­cals ready for the main­stream? No­var­tis, Bris­tol My­ers Squibb bet yes on MP­M's plat­form take

5 years ago
Financing

Got a rev­o­lu­tion­ary health­care com­pa­ny? Bob Nelsen, Jeff Lei­den’s SPAC has $500M to take it pub­lic

5 years ago
Financing

Lit­tle Apel­lis is arm­ing it­self for a David and Go­liath bat­tle over a block­buster drug fran­chise

5 years ago
R&D

Eli Lil­ly’s Covid-19 drug bam­lanivimab is no longer dis­trib­uted in 3 states be­cause of a vari­ant, Wood­cock says

5 years ago
FDA+
Coronavirus

Lack of ear­ly ef­fi­ca­cy for Trans­late Bio's mR­NA-based cys­tic fi­bro­sis drug rais­es some big ques­tions

5 years ago
R&D

De­nied top job, Mike Nal­ly ex­its chief mar­ket­ing job at Mer­ck as the big C-suite shake­up con­tin­ues

5 years ago
People

New Pur­due bank­rupt­cy plan round­ly crit­i­cized as Sack­lers of­fer $4B+; Sana seals pact with Fu­ji­film for iP­SC-de­rived ...

5 years ago
News Briefing

Dean Li in­vites an­oth­er un­der-the-radar biotech to Mer­ck­'s deal­mak­ing ta­ble as Am­ath­us signs neu­rode­gen­er­a­tion pact

5 years ago
Deals

Eu­rope mulls halt­ing Covid-19 vac­cine ex­ports to some coun­tries

5 years ago
Pharma
FDA+

A de­part­ing CMO pens a sad farewell as he heads back to the UK bio­phar­ma scene

5 years ago
People
Bioregnum

Court win for Eli Lil­ly halts HHS’s drug dis­count rule

5 years ago
Pharma
FDA+

Hunt­ing uni­corn sta­tus, the co-in­ven­tors of the Ox­ford-As­traZeneca vac­cine raise a mon­ster B round

5 years ago
Financing

Af­ter a roller coast­er ride, Sage COO strikes out on his own to chart a new biotech path

5 years ago
People

Covid-19 roundup: Al­ny­lam, Vir qui­et­ly de­pri­or­i­tize Covid-19 drug; Da­ta sug­gest As­traZeneca's vac­cine is on­ly 10.4% ...

5 years ago
Coronavirus

An­oth­er blue­bird ex­ec jumps ship as ques­tions swirl over gene ther­a­pies and im­mi­nent split

5 years ago
People
Cell/Gene Tx

Mon­tre­al AI start­up with a tout­ed ad­vi­sor li­cens­es its 'few-shot' plat­form to Re­pare for syn­thet­ic lethal­i­ty ...

5 years ago
Deals
Discovery

Eli Lil­ly, No­var­tis back a biotech start­up boast­ing 'best of both world­s' pro­tein de­graders

5 years ago
Financing

Fresh out of the blue­bird bio on­col­o­gy split, Joanne Smith-Far­rell flies the coop to Be Bio and its B cell plat­form

5 years ago
People
Cell/Gene Tx

FTC pledges to ag­gres­sive­ly crack down on phar­ma merg­ers

5 years ago
Pharma
FDA+

Roche builds long-term case for Evrys­di with 2-year SMA da­ta; Ex­e­Vir nets $50M Se­ries A for lla­ma-de­rived Covid ...

5 years ago
News Briefing

Covid-19 roundup: As As­traZeneca deals with vac­cine woes, US turns at­ten­tion to its an­ti­body treat­ment; Mod­er­na dos­es ...

5 years ago
Coronavirus
First page Previous page 735736737738739740741 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times